Cagrilintide vs Retatrutide
A side-by-side research comparison of Cagrilintide and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cagrilintide | Retatrutide |
|---|---|---|
| Full name | Cagrilintide (AM833) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Investigational (Phase III) | Phase 3 Clinical Trial |
| Mechanism | Acts as a dual amylin and calcitonin receptor agonist. It engages satiety centers in the area postrema and hindbrain, reducing food intake and slowing gastric emptying through a pathway distinct from GLP-1. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | ~3963 Da | 5,200 Da (approximate) |
| Half-life | ~7-8 days | 6 days |
| Bioavailability | High via subcutaneous injection | High (SubQ) |
| Typical dose | 0.3-2.4 mg (titrated) | 1-2 mg → titrate up to 12 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Cagrilintide reported benefits
- Appetite suppression and increased satiety
- Meaningful weight loss
- Complements GLP-1 agonists (additive effect)
- Slows gastric emptying
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.